-- Posts 33% Sales Growth from Continuing Operations in the Fourth Quarter
2007
-- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical
Imaging
-- Reaffirms Expected Non-GAAP EPS CAGR of at least 15% from 2007 Base
Through 2010, Subject to Certain Assumptions
-- Completes Sale of Medical Imaging Business, Reports as Discontinued
Operations, with Fourth Quarter EPS of $0.02 and Full-Year EPS of $0.10
-- Posts Fourth Quarter 2007 GAAP Loss Per Share of $0.07 and 2007 Full
Year GAAP EPS of $0.99 from Continuing Operations, Impacted by Specified
Items
-- Posts Fourth Quarter and Full Year 2007 Non-GAAP EPS of $0.33 and $1.38
from Continuing Operations ($0.35 and $1.48, including Discontinued
Operations), Exceeding Top End of Non-GAAP Guidance Range
NEW YORK, Jan. 31 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb
Company (NYSE: BMY) today reported financial results for the fourth quarter
and twelve months ended December 31, 2007 and revised 2008 earnings
guidance primarily to reflect the sale of the Medical Imaging business.
Bristol-Myers Squibb posted fourth quarter 2007 net sales from
continuing operations of $5.4 billion, an increase of 33%, including a 5%
favorable foreign exchange impact, compared to the same period in 2006.
Excluding the estimated adverse impact of generic competition for PLAVIX(R)
in 2006, net sales from continuing operations increased 13%. The company
reported a fourth quarter 2007 net loss from continuing operations of $133
million, or a loss of $0.07 per diluted share, under U.S. Generally
Accepted Accounting Principles (GAAP), compared to a net loss from
continuing operations of $170 million, or a loss of $0.09 per diluted share
for the same period in 2006. The 2007 results include charges of $292
million associated with the implementation of the previously announced
Productivity Transformation Initiative, an in-process research and
development charge of $230 million in connection with the acquisition of
Adnexus Therapeutics (Adnexus) and an impairment charge of $275 million on
the company's investments in auction rate securities. On a non- GAAP basis
excluding specified items, fourth quarter 2007 net earnings from continuing
operations were $654 million, or $0.33 per diluted share, compared to $344
million, or $0.18 per diluted share for the same period in 2006.
On January 8, 2008, the company completed the sale of its Medical
Imaging business for approximately $525 million, which is presented as a
discontinued operation. Included in discontinued operations were fourth
quarter net sales of $142 million and $156 million in 2007 and 2006,
respectively, and basic and diluted earnings per share of $0.02 in the
fourth quarters of 2007 and 2006.
"We are moving forward with important strategic actions that are
helping us advance our pipeline, increase productivity and transform to a
Next Generation BioPharma company," said James M. Cornelius, chief
executive officer, Bristol-Myers Squibb. "Our underlying operating
performance this quarter was strong, demonstrating the power of our
medicines to help even more people prevail in their fight against serious
diseases. The sale of Medical Imaging has strengthened our ability to
consider future acquisitions that add to our capabilities, portfolio and
pipeline of biotech and specialty medicines. And our Productivity
Transformation Initiative, which helps identify ways to operate more
efficiently, has spawned a new culture of continuous improvement."
For the twelve months ended December 31, 2007, net sales from
continuing operations increased 12%, including a 3% favorable foreign
exchange impact, to $19.3 billion compared to the same period in 2006. Net
earnings from continuing operations in the twelve months of 2007 on a GAAP
basis were $2.0 billion, or $0.99 per diluted share, compared to $1.4
billion, or $0.73 per diluted share for the same period last year. On a
non-GAAP basis, excluding specified items, Bristol-Myers Squibb reported
net earnings from continuing operations of $2.7 billion, or $1.38 per
diluted share for the twelve months ended December 31, 2007, compared to
$2.0 billion, or $1.01 per diluted share for the same period last year.
Included in discontinued operations were Medical Imaging full year 2007 and
2006 net sales of $629 million and $658 million, respectively, and basic
and diluted earnings per share of $0.10 and $0.08 in 2007 and 2006,
respectively.
NEW PRODUCT AND PIPELINE DEVELOPMENTS
In December, the European Commission granted marketing authorization
for ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil
fumarate 300 mg), formally approving ATRIPLA(R) for commercialization in
the 27 countries of the European Union, as well as in Norway and Iceland.
ATRIPLA(R) has been launched in the United Kingdom, Germany and Austria.
In December, Bristol-Myers Squibb and Medarex, Inc. announced top-line
data from three registrational trials that constitute the monotherapy
program for ipilimumab in patients with metastatic melanoma. The companies
plan to meet with regulatory agencies in the near future to discuss
possible regulatory pathways forward based on these data.
In November, Bristol-Myers Squibb and Pierre Fabre Medicament announced
the termination of the license agreement for the development of vinflunine,
a chemotherapy agent under investigation for the treatment of advanced or
metastatic bladder cancer and other tumor types.
In November, ABILIFY(R) (aripiprazole) was approved by the Food and
Drug Administration (FDA) as adjunctive, or add-on, treatment to
antidepressant therapy (ADT) in adults with major depressive disorder
(MDD). ABILIFY(R) is the first medication approved by the FDA as add-on
treatment for MDD. The FDA also approved ABILIFY(R) for the treatment of
schizophrenia in adolescent patients (ages 13-17) and accepted for Priority
Review the supplemental New Drug Application (sNDA) for the treatment of
pediatric patients (ages 10-17) with Bipolar I Disorder.
In November, the FDA approved new labeling for SPRYCEL(TM) to include a
lower recommended starting dose of 100 mg once daily and safety and
efficacy data in a greater number of patients with chronic-phase chronic
myeloid leukemia (CML) resistant or intolerant to prior therapy including
GLEEVEC(R) (imatinib mesylate). The previous recommending starting dose was
70 mg twice daily.
In October, the company launched IXEMPRA(TM) (ixabepilone), for the
treatment of patients with metastatic or locally advanced breast cancer, in
the U.S. In addition, the Japanese New Drug Application for ixabepilone was
submitted in December, and the Marketing Authorization Application for
ixabepilone is under review by the European Medicines Evaluation Agency
following submission in September.
PRODUCTIVITY TRANSFORMATION INITIATIVE
The company undertook a broad range of actions in the fourth quarter as
part of the previously announced, three-year Productivity Transformation
Initiative, which is reducing costs, streamlining operations and
rationalizing global manufacturing. The initiative, which is on track to
achieve $1.5 billion in cost savings and cost avoidance by 2010, is central
to the company's strategy to become a more nimble and flexible Next
Generation BioPharma enterprise. In line with the previously announced
guidance, the company recorded a $292 million charge in the fourth quarter
in connection with the initiative. Among the many productivity activities
across the entire company this quarter, the company announced the impending
closure of several manufacturing facilities, including Barceloneta, Puerto
Rico and Mayaguez, Puerto Rico.
FOURTH QUARTER RESULTS
-- Fourth quarter 2007 net sales from continuing operations increased 33%
to $5.4 billion, including a 5% favorable foreign exchange impact
compared to the same period in 2006. U.S. net sales from continuing
operations increased 51% to $3.0 billion for the quarter compared to
2006, primarily due to increased PLAVIX(R) sales, as well as the
continued growth of key and newer products. International net sales
from continuing operations increased 15% to $2.4 billion, including a
10% favorable foreign exchange impact.
-- Cost of products sold, as a percentage of net sales, decreased to 33.8%
in the fourth quarter of 2007 compared to 34.4% in the same period in
2006. The margin improvement was primarily due to sales growth of
higher margin products in 2007.
-- Marketing, selling and administrative expenses increased by 5% to $1.3
billion in the fourth quarter of 2007 compared to the same period in
2006, primarily due to foreign exchange impact.
-- Advertising and product promotion spending increased by 16% to $483
million in the fourth quarter of 2007 from $415 million in the same
period in 2006, driven primarily by increased spending for
direct-to-consumer advertising for PLAVIX(R), ABILIFY(R) and
ORENCIA(R), as well as investments to support the launch of
IXEMPRA(TM).
-- Research and development expenses increased 42% to $1,138 million in
the fourth quarter of 2007 from $799 million in the same period in
2006. This increase primarily reflects the in-process research and
development charge of $230 million in 2007 in connection with the
acquisition of Adnexus.
INCOME TAXES
The effective tax rate on income from continuing operations before
minority interest and income taxes was 67.8% for the three months ended
December 31, 2007, compared with a tax benefit of 54.3% on the loss from
continuing operations before minority interest and income taxes for the
three months ended December 31, 2006. The fourth quarter 2007 tax rate was
impacted by an impairment on the company's investment in certain financial
instruments with no tax benefit and the non-deductible write-off of
acquired in-process research & development expenses related to the
acquisition of Adnexus. The fourth quarter 2006 tax benefit was in part
attributable to the reinstatement of the U. S. Federal Research and
Development credit in December 2006, which was partially offset by the
treatment of provisions for a portion of certain litigation reserves as
non-deductible.
SPECIFIED ITEMS, INCLUDING IMPAIRMENT CHARGE
In the three months ended December 31, 2007 and 2006, the company
recorded specified income and expense items that affected the comparability
of the results. This included fourth quarter 2007 charges of $292 million
in connection with the execution of the previously announced Productivity
Transformation Initiative, $230 million for acquired in-process research
and development relating to the acquisition of Adnexus and $275 million
relating to an impairment of the company's investment in certain auction
rate securities (ARS).
As of December 31, 2007, the company had approximately $2.2 billion of
cash, cash equivalents and short-term marketable securities. In addition,
the company had $811 million of principal invested in ARS. The ARS held by
the company are private placement securities with long-term nominal
maturities for which the interest rates are reset through a dutch auction
each month. The monthly auctions historically have provided a liquid market
for these securities. The company's investments in ARS represent interests
in collateralized debt obligations supported by pools of residential and
commercial mortgages or credit cards, insurance securitizations and other
structured credits, including corporate bonds. Some of the underlying
collateral for the ARS held by the company consists of sub-prime mortgages.
Consistent with the company's investment policy guidelines, the ARS
investments held by the company all had AAA/Aaa credit ratings at the time
of purchase. With the liquidity issues experienced in global credit and
capital markets, the ARS held by the company at December 31, 2007 have
experienced multiple failed auctions as the amount of securities submitted
for sale has exceeded the amount of purchase orders. In addition, in the
fourth quarter of 2007, $79 million of principal invested in ARS held by
the company were downgraded and others were placed on credit watch. All of
these securities retain at least one AAA rating.
The estimated market value of the company's ARS holdings at December
31, 2007 was $419 million, which reflects a $392 million adjustment to the
principal value of $811 million. Although the ARS continue to pay interest
according to their stated terms, based on third-party valuation models and
an analysis of other-than-temporary impairment factors, the company has
recorded an impairment charge of $275 million in the fourth quarter,
reflecting the portion of ARS holdings that the company has concluded have
an other-than- temporary decline in value. In addition, the company
recorded an unrealized pre-tax loss of $142 million in other comprehensive
income as a reduction in shareholders' equity, reflecting $117 million of
adjustments to ARS holdings and $25 million of other marketable securities
that the company has concluded have a temporary decline in value. The $275
million impairment charge does not have a material impact on the company's
liquidity or financial flexibility.
Historically, given the liquidity created by the auctions, ARS were
presented as current assets under marketable securities on the company's
balance sheet. Given the failed auctions, the company's ARS are illiquid
until there is a successful auction for them. Accordingly, the entire
amount of such remaining ARS has been reclassified from current to
non-current assets on the company's balance sheet.
If uncertainties in the credit and capital markets continue, these
markets deteriorate further or the company experiences any additional
ratings downgrades on any investments in its portfolio (including on ARS),
the company may incur additional impairments to its investment portfolio,
which could negatively affect the company's financial condition, cash flow
and reported earnings. The company believes that based on the company's
current cash, cash equivalents and marketable securities balances of $2.2
billion at December 31, 2007 and expected operating cash flows, the current
lack of liquidity in the credit and capital markets will not have a
material impact on the company's liquidity, cash flow, financial
flexibility or its ability to fund its operations, including the dividend.
For information on specified items, see Appendix 2. Details reconciling
these non-GAAP amounts with GAAP amounts including specified items are
provided in Appendix 1 attached and in supplemental materials available on
the company's website.
PHARMACEUTICALS
Worldwide pharmaceutical sales increased 39% to $4.4 billion in the
fourth quarter of 2007, including a 5% favorable foreign exchange impact,
compared to the same period in 2006.
U.S. pharmaceutical sales increased 65% to $2.5 billion in the fourth
quarter of 2007 compared to the same period in 2006, primarily due to
increased PLAVIX(R) sales, as well as the continued growth of ABILIFY(R),
REYATAZ(R), the SUSTIVA(R) Franchise and ERBITUX(R), and sales of newer
products ORENCIA(R), BARACLUDE(R), SPRYCEL(TM) and IXEMPRA(TM).
International pharmaceutical sales increased 16%, including a 10%
favorable foreign exchange impact, to $1.9 billion in the fourth quarter of
2007 compared to the same period in 2006. The increase was primarily due to
sales growth in REYATAZ(R) and ABILIFY(R) and newer products ORENCIA(R),
BARACLUDE(R) and SPRYCEL(TM), partially offset by increased generic
competition for PRAVACHOL(R) and TAXOL(R). The company's reported
international sales do not include copromotion sales reported by its
alliance partner, sanofi-aventis, for PLAVIX(R) and AVAPRO(R)/AVALIDE(R),
which continue to show growth in the fourth quarter of 2007.
Product Sales
-- Sales of PLAVIX(R), a platelet aggregation inhibitor that is part of
the company's alliance with sanofi-aventis increased 177%, including a
4% favorable foreign exchange impact, to $1,374 million in the fourth
quarter of 2007, from $496 million in the same period in 2006. Sales
of PLAVIX(R) increased in the U.S. to $1,178 million in the fourth
quarter of 2007 from $343 million in the same period in 2006. The
comparison to the fourth quarter 2006 sales reflects the adverse impact
of generic competition for PLAVIX(R) in 2006, which the company
estimates to be in the range of $700 million to $750 million.
Estimated total U.S. prescription demand for clopidogrel bisulfate
(branded and generic) increased by 6% in the fourth quarter of 2007
compared to 2006. Estimated total U.S. prescription demand for branded
PLAVIX(R) increased by 295% in the same period.
-- Sales of AVAPRO(R)/AVALIDE(R), an angiotensin II receptor blocker for
the treatment of hypertension, also part of the sanofi-aventis
alliance, increased 7%, including a 5% favorable foreign exchange
impact, to $328 million in the fourth quarter of 2007 from $307 million
in the same period in 2006. U.S. sales increased 1% to $183 million in
the fourth quarter of 2007 from $182 million in the same period in
2006. Estimated total U.S. prescription demand decreased approximately
5% compared to 2006. International sales increased 16%, including a
13% favorable foreign exchange impact, to $145 million compared to $125
million in the same period in 2006.
-- Total revenue for ABILIFY(R), an antipsychotic agent for the treatment
of schizophrenia, acute bipolar mania and bipolar disorder, increased
28%, including a 3% favorable foreign exchange impact, to $462 million
in the fourth quarter of 2007 from $362 million in the same period in
2006. U.S. sales increased 23% to $361 million in the fourth quarter
2007 from $294 million in the same period in 2006, primarily due to
higher demand and higher average net selling prices. Estimated total
U.S. prescription demand increased approximately 11% compared to the
same period last year. International sales increased 49%, including a
16% favorable foreign exchange impact, to $101 million in the fourth
quarter of 2007 from $68 million in the same period in 2006, due to
continued growth across European markets. Total revenue for ABILIFY(R)
primarily consists of alliance revenue representing the company's 65%
share of net sales in countries where it copromotes with Otsuka
Pharmaceutical Co., Ltd.
-- Sales of REYATAZ(R), a protease inhibitor for the treatment of human
immunodeficiency virus (HIV), increased 31%, including a 5% favorable
foreign exchange impact, to $334 million in the fourth quarter of 2007
from $255 million in the same period in 2006. U.S. sales increased 15%
to $165 million in the fourth quarter of 2007 from $144 million in the
same period in 2006, primarily due to higher demand. Estimated total
U.S. prescription demand increased approximately 12% compared to 2006.
International sales increased 52%, including an 11% favorable foreign
exchange impact, to $169 million in the fourth quarter of 2007 from
$111 million in the same period in 2006 primarily due to increased
demand in Latin America and Europe.
-- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse
transcriptase inhibitor for the treatment of HIV, increased 17%,
including a 5% favorable foreign exchange impact, to $260 million in
the fourth quarter of 2007 from $222 million in the same period in
2006. U.S. sales increased 13% to $162 million in the fourth quarter
of 2007 from $144 million in the same period in 2006, primarily due to
higher demand of ATRIPLA(TM). Estimated total U.S. prescription demand
increased approximately 15% compared to 2006. International sales
increased 26%, including a 13% favorable foreign exchange impact, to
$98 million in the fourth quarter of 2007 from $78 million in the same
period in 2006. Total revenue for the SUSTIVA(R) Franchise includes
sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in
the combination therapy ATRIPLA(TM), which is sold through a joint
venture in the U.S. and Canada with Gilead Sciences, Inc.
-- Sales of BARACLUDE(R), an oral antiviral agent for the treatment of
chronic hepatitis B, increased 175%, including a 13% favorable foreign
exchange impact, to $99 million in the fourth quarter of 2007 from $36
million in the same period in 2006, due to continued growth across all
markets.
-- Sales of ORENCIA(R), a fusion protein indicated for adult patients with
moderate to severe rheumatoid arthritis launched in 2006, increased
134%, including a 3% favorable foreign exchange impact, to $75 million,
in the fourth quarter of 2007 from $32 million in the same period in
2006.
-- Sales of ERBITUX(R), which is sold by the company almost exclusively in
the U.S., increased 11% to $185 million in the fourth quarter of 2007
from $167 million in the same period in 2006, due to growth in the use
for head and neck and colorectal cancer. ERBITUX(R) is marketed by the
company under a distribution and copromotion agreement with ImClone
Systems Incorporated.
-- Sales for SPRYCEL(TM), an oral inhibitor of multiple tyrosine kinases,
increased to $56 million in the fourth quarter of 2007 from $14 million
in the same period in 2006. This was due to launches in international
markets beginning in the fourth quarter of 2006 and the continued
growth in the U.S.
-- Sales of IXEMPRA(TM), a microtubule inhibitor for the treatment of
patients with metastatic or locally advanced breast cancer, were $15
million in the fourth quarter of 2007. IXEMPRA(TM) was launched in the
U.S. in October 2007.
HEALTH CARE GROUP
The combined fourth quarter 2007 revenues for the Health Care Group
increased 9%, including a 5% favorable foreign exchange impact, to $1.0
billion compared to the same period in 2006. On January 8, 2008, the
company completed the sale of Medical Imaging, which is presented as a
discontinued operation.
Nutritionals
-- Worldwide Nutritional sales increased 8%, including a 4% favorable
foreign exchange impact, to $670 million in the fourth quarter of 2007
from $618 million in the same period in 2006. U.S. Nutritional sales
decreased 7% to $275 million in the fourth quarter of 2007, primarily
due to contract transitions under the Women, Infants and Children (WIC)
program. International Nutritional sales increased 22% to $395 million
in the fourth quarter of 2007, including a 9% favorable foreign
exchange impact, primarily due to increased sales in infant formula and
broad-based growth in Asia and Latin America.
ConvaTec
-- Worldwide ConvaTec sales increased 11%, including a 7% favorable
foreign exchange impact, to $323 million in the fourth quarter of 2007
from $291 million in the same period in 2006. Sales of wound
therapeutic products increased 11%, including a 7% favorable foreign
exchange impact, to $136 million in the fourth quarter of 2007 from
$123 million in the same period in 2006, primarily due to continued
growth of AQUACEL(R).
2008 GUIDANCE
Bristol-Myers Squibb revises its 2008 earnings guidance for fully
diluted earnings per share from continuing operations on a GAAP basis to be
between $1.36 and $1.46 from $1.44 to $1.54, primarily reflecting the
impact from the sale of the Medical Imaging business. The revised GAAP
guidance includes estimated charges of approximately $500 million related
to implementation of the Productivity Transformation Initiative, which will
be dependent on timing of implementation and accounting treatment.
The company also revises its 2008 fully diluted earnings per share from
continuing operations guidance on a non-GAAP basis to be between $1.60 and
$1.70 from $1.65 to $1.75, primarily reflecting the impact of the Medical
Imaging divestiture. The non-GAAP guidance excludes specified items as
discussed under "Use of Non-GAAP Financial Information." Details
reconciling adjusted non-GAAP amounts with the amounts reflecting specified
items are provided in supplemental materials available on the company's
website.
Further, the 2008 guidance excludes other specified items such as gains
or losses from sale of businesses and product lines; from sale of equity
investments and from discontinuations of operations; restructuring items
that meet the requirements of SFAS 112 for severance and SFAS 146 for other
exit costs; accelerated depreciation charges under SFAS 144 related to
restructuring items described above; asset impairments; charges and
recoveries relating to significant legal proceedings; upfront and milestone
payments for in-licensing of products that have not achieved regulatory
approval that are immediately expensed; copromotion or alliance charges and
payments for in- process research and development which under GAAP are
immediately expensed rather than amortized over the life of the agreement;
income from upfront and milestone payments that is immediately recognized
for out-licensing of products, including deferred income recognized upon
termination; and significant tax events.
The company reaffirms guidance that it expects non-GAAP earnings per
share from continuing operations to grow at a minimum of 15 percent
compounded annual growth rate, from the 2007 base, for the next three
years, excluding costs associated with the Productivity Transformation
Initiative and other specified items that have not yet been identified and
quantified. The guidance assumes certain other assumptions including mid to
high single digit sales growth, continued improvement in its pharmaceutical
margins driven by rationalization of its manufacturing network, flat
marketing, selling and administrative expense over the time period with
productivity initiatives offsetting investments in new product launches,
mid single digit growth in research and development spending, and an
increase in the effective tax rate from 2008 levels.
The financial guidance for 2008 and the three-year compound annual
growth rate further assume that the company and its product partner,
sanofi-aventis, maintain exclusivity for the PLAVIX(R) patent through at
least 2010.
As previously disclosed, the composition of matter patent for
PLAVIX(R), which expires in 2011, is subject to litigation in the U.S. with
Apotex Inc. and Apotex Corp. (Apotex). Apotex's appeal of the U.S. District
Court decision upholding the validity and enforceability of the main patent
protection for PLAVIX(R) is still pending before the U.S. Court of Appeals
for the Federal Circuit. Activities relating to the damages phase of the
litigation in the U.S. District Court continue to proceed.
Even though the company and its alliance partner, sanofi-aventis,
prevailed in the U.S. District Court, if Apotex were to prevail on appeal,
the company could expect to face renewed generic competition for PLAVIX(R)
promptly thereafter. There are other pending PLAVIX(R) patent litigations
in the United States and in other less significant markets for the product.
The company continues to believe that the PLAVIX(R) patents are valid and
infringed, and with its alliance partner, sanofi-aventis, is vigorously
pursuing these cases.
It is not possible at this time reasonably to assess the ultimate
outcome of the appeal by Apotex of the patent litigation or of the other
PLAVIX(R) patent litigations, or the timing of any renewed generic
competition for PLAVIX(R) from Apotex or additional generic competition for
PLAVIX(R) from other generic pharmaceutical companies. Loss of market
exclusivity of PLAVIX(R) and/or the development of sustained generic
competition would be material to the company's sales of PLAVIX(R), results
of operations and cash flows, and could be material to the company's
financial condition and liquidity. PLAVIX(R) is the company's largest
product by net sales, and U.S. net sales for PLAVIX(R) were $4.1 billion
and $2.7 billion in 2007 and 2006, respectively.
Use of Non-GAAP Financial Information
This press release contains non-GAAP earnings and earnings per share
information adjusted to exclude certain costs, expenses, gains and losses
and other specified items. Among the items in GAAP earnings but excluded
for purposes of determining adjusted earnings are: charges related to
implementation of the Productivity Transformation Initiative; gains or
losses from sale of businesses and product lines; from sale or write-down
of equity investments and from discontinuations of operations;
restructuring items that meet the requirements of SFAS 112 for severance
and SFAS 146 for other exit costs; accelerated depreciation charges under
SFAS 144 related to restructuring items described above; asset impairments;
charges and recoveries relating to significant legal proceedings; upfront
and milestone payments for in-licensing of products that have not achieved
regulatory approval that are immediately expensed; co promotion or alliance
charges and payments for in- process research and development which under
GAAP are immediately expensed rather than amortized over the life of the
agreement; income from upfront and milestone payments that is immediately
recognized for out-licensing of products, including deferred income
recognized upon termination; costs of early debt retirement; impairments to
marketable securities; and significant tax events. This information is
intended to enhance an investor's overall understanding of the company's
past financial performance and prospects for the future. For example,
non-GAAP earnings per share information is an indication of the company's
baseline performance before items that are considered by the company to be
not reflective of the company's ongoing results. In addition, this
information is among the primary indicators the company uses as a basis for
evaluating company performance, allocating resources, setting incentive
compensation targets, and planning and forecasting of future periods. This
information is not intended to be considered in isolation or as a
substitute for diluted earnings per share prepared in accordance with GAAP.
Statement on Cautionary Factors
This press release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to goals, plans and
projections regarding the company's financial position, results of
operations, market position, product development and business strategy.
These statements may be identified by the fact that they use words such as
"anticipate", "estimates", "should", "expect", "guidance", "project",
"intend", "plan", "believe" and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including
factors that could delay, divert or change any of them, and could cause
actual outcomes and results to differ materially from current expectations.
These factors include, among other things, market factors, (including
whether uncertainties in the credit and capital markets or a further
deterioration of these markets will lead to future impairments to the
company's investment portfolio) competitive product development, pricing
controls and pressures (including changes in rules and practices of managed
care groups and institutional and governmental purchasers), economic
conditions such as interest rate and currency exchange rate fluctuations,
judicial decisions and governmental laws and regulations related to
Medicare, Medicaid and healthcare reform, pharmaceutical rebates and
reimbursement, claims and concerns that may arise regarding the safety and
efficacy of in- line products and product candidates, changes to wholesaler
inventory levels, variability in data provided by third parties, changes
in, and interpretation of, governmental regulations and legislation
affecting domestic or foreign operations, including tax obligations,
difficulties and delays in product development, manufacturing or sales,
patent positions and the ultimate outcome of any litigation matter,
including whether Apotex will prevail in its appeal of the District court's
decision in the PLAVIX(R) patent litigation. These factors also include the
company's ability to execute successfully its strategic plans, including
its productivity transformation initiatives, the expiration of patents on
certain other products, and the impact and result of governmental
investigations. There can be no guarantees with respect to pipeline
products that future clinical studies will support the data described in
this release, that the products will receive necessary regulatory
approvals, or that they will prove to be commercially successful; nor are
there guarantees that regulatory approvals will be sought, or sought within
currently expected timeframes, or that contractual milestones will be
achieved. For further details and a discussion of these and other risks and
uncertainties, see the company's periodic reports, including current
reports on Form 8-K, quarterly reports on Form 10-Q and the annual report
on Form 10- K, furnished to and filed with the Securities and Exchange
Commission. The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
Company and Conference Call Information
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company whose mission is to extend and enhance human life.
There will be a conference call on January 31, 2008 at 10:00 a.m. (EDT)
during which company executives will address inquiries from investors and
analysts. Investors and the general public are invited to listen to a live
web cast of the call at http://www.bms.com/iror by dialing 913-312-0980. Materials
related to the call will be available at the same website prior to the
call.
For more information, contact: Wilson Grabill, 212-546-4377,
Communications, Rebecca Goldsmith, 212-546-2793, Communications, John
Elicker, 212-546-3775, Investor Relations, or Suketu Desai, 609-252-5796,
Investor Relations.
ABILIFY(R) is the trademark of Otsuka Pharmaceutical Co., Ltd.
ATRIPLA(TM) is a trademark of both Bristol-Myers Squibb Co. and Gilead
Sciences, Inc.
AVAPRO(R), AVALIDE(R) and PLAVIX(R) are trademarks of sanofi-aventis
Erbitux(R) is a trademark of ImClone Systems Incorporated
BRISTOL-MYERS SQUIBB COMPANY
NET SALES FROM CONTINUING OPERATIONS BY OPERATING SEGMENT
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, dollars in millions)
Three Months Twelve Months
Ended December 31, Ended December 31,
2007 2006 2007 2006
Pharmaceuticals $4,388 $3,148 $15,622 $13,861
Nutritionals 670 618 2,571 2,347
ConvaTec 323 291 1,155 1,048
Health Care Group 993 909 3,726 3,395
Net Sales from continuing
operations $5,381 $4,057 $19,348 $17,256
BRISTOL-MYERS SQUIBB COMPANY
SELECTED PRODUCTS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, dollars in millions)
The following table sets forth worldwide and U.S. reported net sales
for selected products for the three and twelve months ended December 31,
2007 compared to the three and twelve months ended December 31, 2006. In
addition, the table includes, where applicable, the estimated total U.S.
prescription change for the retail and mail-order channels for the
comparative periods presented for certain of the company's U.S.
pharmaceutical products based on third-party data. A significant portion of
the company's U.S. pharmaceutical sales is made to wholesalers. Where
changes in reported net sales differ from prescription growth, this change
in net sales may not reflect underlying prescriber demand.
Worldwide Net Sales U.S. Net Sales
% Change in
U.S. Total
Prescriptions
2007 2006 %Change 2007 2006 %Change vs. 2006
Three Months Ended
December 31,
Pharmaceuticals
Cardiovascular
Plavix $1,374 $496 177 % $1,178 $343 ** **
Avapro/Avalide 328 307 7 % 183 182 1 % (5)%
Pravachol 90 146 (38)% 18 50 (64)% (80)%
Coumadin 53 57 (7)% 43 48 (10)% (14)%
Virology
Reyataz 334 255 31 % 165 144 15 % 12 %
Sustiva Franchise
(total revenue) 260 222 17 % 162 144 13 % 15 %
Baraclude 99 36 175 % 29 18 61 % 59 %
Oncology
Erbitux 185 167 11 % 182 165 10 % N/A
Taxol 114 130 (12)% 5 2 150 % N/A
Sprycel 56 14 ** 17 11 55 % 96 %
Ixempra 15 - - 15 - - N/A
Affective Psychiatric)
Disorders
Abilify (total
revenue) 462 362 28 % 361 294 23 % 11 %
Immunoscience
Orencia 75 32 134 % 66 31 113 % N/A
Other Pharmaceuticals
Efferalgan 87 74 18 % - - - N/A
Nutritionals
Enfamil 280 271 3 % 179 190 (6)% N/A
Enfagrow 79 67 18 % - - - N/A
ConvaTec
Ostomy 167 151 11 % 47 45 4 % N/A
Wound Therapeutics 136 123 11 % 43 43 - N/A
** Change is in excess of 200%.
Worldwide Net Sales U.S. Net Sales
% Change in
U.S. Total
Prescriptions
2007 2006 %Change 2007 2006 %Change vs. 2006
Twelve Months Ended
December 31,
Pharmaceuticals
Cardiovascular
Plavix $4,755 $3,257 46 % 4,060 2,655 53 % 34 %
Avapro/Avalide 1,204 1,097 10 % 692 647 7 % (4)%
Pravachol 443 1,197 (63)% 139 553 (75)% (82)%
Coumadin 201 220 (9)% 164 186 (12)% (16)%
Virology
Reyataz 1,124 931 21 % 587 514 14 % 13 %
Sustiva Franchise
(total revenue) 956 791 21 % 604 495 22 % 20 %
Baraclude 275 83 ** 88 50 76 % 77 %
Oncology
Erbitux 692 652 6 % 683 646 6 % N/A
Taxol 422 563 (25)% 14 12 17 % N/A
Sprycel 158 25 ** 58 22 164 % **
Ixempra 15 - - 15 - - N/A
Affective
(Psychiatric)
Disorders
Abilify (total
revenue) 1,660 1,282 29 % 1,305 1,052 24 % 12 %
Immunoscience
Orencia 231 89 160 % 216 88 145 % N/A
Other Pharmaceuticals
Efferalgan 308 266 16 % - - - N/A
Nutritionals
Enfamil 1,082 1,007 7 % 722 688 5 % N/A
Enfagrow 295 262 13 % - - - N/A
ConvaTec
Ostomy 594 554 7 % 164 159 3 % N/A
Wound Therapeutics 488 441 11 % 149 143 4 % N/A
** Change is in excess of 200%.
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, amounts in millions except per share data)
Three Months Twelve Months
Ended December 31, Ended December 31,
2007 2006 2007 2006
Net Sales $5,381 $4,057 $19,348 $17,256
Cost of products sold 1,817 1,395 6,218 5,739
Marketing, selling and administrative 1,343 1,284 4,855 4,800
Advertising and product promotion 483 415 1,465 1,340
Research and development 908 799 3,282 2,991
Acquired in-process research and
development 230 - 230 -
Provision for restructuring, net 139 53 183 59
Litigation expense, net - 346 14 302
Gain on sale of product assets - - (273) (200)
Equity in net income of affiliates (131) (138) (524) (474)
Other expense, net (a) 331 240 364 299
5,120 4,394 15,814 14,856
Earnings/(Loss) from Continuing Operations
Before Minority Interest and Income Taxes 261 (337) 3,534 2,400
Provision/(Benefit) for income taxes 177 (183) 803 538
Minority interest, net of taxes 217 16 763 440
Net (Loss)/Earnings from Continuing
Operations (133) (170) 1,968 1,422
Net Earnings from Discontinued Operations 44 36 197 163
Net (Loss)/Earnings $(89) $(134) $2,165 $1,585
Earnings per Common Share
Basic:
Net (Loss)/Earnings from Continuing
Operations $(.07) $(.09) $1.00 $.73
Net Earnings from Discontinued
Operations .02 .02 .10 .08
Net (Loss)/Earnings per Common Share $(.05) $(.07) $1.10 $.81
Diluted:
Net (Loss)/Earnings from Continuing
Operations $(.07) $(.09) $.99 $.73
Net Earnings from Discontinued
Operations .02 .02 .10 .08
Net (Loss)/Earnings per Common Share $(.05) $(.07) $1.09 $.81
Average Common Shares Outstanding:
Basic 1,975 1,961 1,970 1,960
Diluted 1,975 1,961 1,980 1,963
(a) Other expense, net
Interest expense $97 $128 $422 $498
Interest income (57) (73) (241) (274)
Foreign exchange transaction losses 1 6 28 6
Other expense, net 290 179 155 69
$331 $240 $364 $299
APPENDIX 1
BRISTOL-MYERS SQUIBB COMPANY
DILUTED EARNINGS PER COMMON SHARE EXCLUDING SPECIFIED ITEMS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, amounts in millions except per share data)
Three Months Twelve Months
Ended December 31, Ended December 31,
2007 2006 2007 2006
Reconciliation of Diluted (Loss)/Earnings
per Common Share from
Continuing Operations:
Diluted (Loss)/Earnings per Common Share
from Continuing Operations $(.07) $(.09) $.99 $.73
Specified Items:
Productivity Transformation Initiative .12 - .12 -
Auction rate securities impairment .14 - .14 -
Upfront and milestone payments and acquired
in-process research and development .12 .01 .17 .02
Downsizing and streamlining of worldwide
operations .02 .04 .06 .10
Gain on sale of properties and product
assets - - (.08) (.06)
Litigation matters - .14 - .13
Debt retirement costs - .07 - .07
Tax item - - (.02) .02
Total Specified Items .40 .26 .39 .28
Diluted Earnings per Common Share from
Continuing Operations and Excluding
Specified Items $.33 $.17 $1.38 $1.01
Reconciliation of Diluted (Loss)/Earnings
per Common Share Including
Discontinued Operations:
Diluted (Loss)/Earnings per Common Share
Including Discontinued Operations $(.05) $(.07) $1.09 $.81
Specified Items noted above .40 .26 .39 .28
Diluted Earnings per Common Share
Including Discontinued Operations and
Excluding Specified Items $.35 $.19 $1.48 $1.09
APPENDIX 2
BRISTOL-MYERS SQUIBB COMPANY SPECIFIED ITEMS
FOR THE THREE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, dollars in millions)
Three months ended December 31, 2007
Acquired
Marketing in-process Provision (Gain)/
Cost selling Research research for Loss on Other
of and and and restruc- sale of (income)
products adminis- devel- devel- uring, product expense,
sold trative opment opment net assets net Total
Productivity
Transformation
Initiative:
Downsizing
and stream-
lining of
worldwide
operations $- $- $- $- $139 - $6 $145
Accelerated
depreciation
and asset
impairment 102 8 - - - - - 110
Process
standar-
dization
implemen-
tation
costs - 5 - - - 32 - 37
102 13 - - 139 32 6 292
Other:
Product
liability - - - - - - 10 10
Upfront and
milestone
payments
and acquired
in-process
research and
development - - 5 230 - - - 235
Auction rate
securities
impairment - - - - - - 275 275
Accelerated
depreciation,
asset
impairment
and contract
termination 31 - - - - - 23 54
Gain on
sale of
properties - - - - - - (9) (9)
$133 $13 $5 $230 $139 $32 $305 857
Income taxes on items above (70)
(Increase)/Decrease to Net Earnings from Continuing Operations $787
Three months ended December 31, 2006
Provision Litigation
for settlement Other
Cost of Research restruct- expense/ expense/
products and uring, (income), (income),
sold development net net net Total
Litigation Matters:
Pharmaceutical
pricing and
sales litigation $- $- $- $353 $- $353
Claim for damages - - - - 13 13
Insurance recovery - - - (7) - (7)
- - - 346 13 359
Other:
Debt retirement costs - - - - 220 220
Downsizing and
streamlining of
worldwide operations - - 53 - - 53
Accelerated depreciation
and asset impairment 29 14 - - - 43
Milestone payments - 35 - - - 35
$29 $49 $53 $346 $233 710
Income taxes on items above (196)
(Increase)/Decrease to Net Earnings from Continuing Operations $514
BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006
(Unaudited, dollars in millions)
Twelve months ended December 31, 2007
Gain)/
Acquired Pro- Loss on
Marketing, in-process vision sale
selling Research research for Litiga- of Other
Cost of and and and restruc- tion pro- (income)
products adminis- devel- devel- uring, expense, duct expense,
sold trative opment opment net /net assets net Total
Productivity
Transformation
Initiative:
Downsizing
and stream-
lining of
worldwide
operations $- $- $- $- $139 $- $- $6 $145
Accelerated
depreciation
and asset
impairment 102 8 - - - - - - 110
Process
standard-
ization
implement-
ation costs - 5 - - - - 32 - 37
102 13 - - 139 - 32 6 292
Other:
Litigation
settlement - - - - - 14 - - 14
Insurance
recovery - - - - - - - (11) (11)
Product
liability - - - - - - - 15 15
Upfront and
milestone
payments and
acquired
in-process
research and
development - - 162 230 - - - - 392
Auction rate
securities
impairment - - - - - - - 275 275
Downsizing
and stream-
lining of
worldwide
operations - - - - 44 - - - 44
Accelerated
depreciation,
asset
impairment
and contract
termination 77 - - - - - - 23 100
Gain on sale
of properties
and product
assets - - - - - - (273) (9) (282)
$179 $13 $162 $230 $183 $14 $(241) $299 839
Income taxes on items above (33)
Change in estimate for taxes on a prior year item (39)
(Increase)/Decrease to Net Earnings from Continuing Operations $767
Twelve months ended December 31, 2006
Marketing, Provision Litigation
selling Research for settlement Gain on Other
Cost of and and restruct- expense/ sale of expense/
products adminis- develop- uring, (income), product (income),
sold trative ment net net asset net Total
Litigation
Matters:
Pharma-
ceutical
pricing
and sales
litigation $ - $ - $ - $ - $ 353 $ - $ - $ 353
Product
liability - - - - - - 11 11
Claim for
damages - - - - - - 13 13
Commercial
litigations - - - - (14) - - (14)
Insurance
recovery - - - - (37) - - (37)
- - - - 302 - 24 326
Other:
Debt
retirement
costs - - - - - - 220 220
Accelerated
depreciation,
asset
impairment
and contract
termination 167 4 15 - - - - 186
Upfront and
milestone
payments - - 70 - - - - 70
Downsizing and
streamlining
of worldwide
operations - - - 59 - - - 59
Gain on sale
of product
asset - - - - - (200) - (200)
$167 $4 $85 $59 $302 $(200) $244 661
Income taxes on items above (149)
Change in estimate for taxes on prior year items 39
(Increase)/Decrease to Net Earnings from Continuing Operations $551
SOURCE Bristol-Myers Squibb Company
 back to top
Related links:
http://www.bms.com
CONTACT:
Media: Wilson Grabill, Communications,
+1-212-546-4377, wilson.grabill@bms.com, or Rebecca Goldsmith,
Communications, +1-212-546-2793, rebecca.goldsmith@bms.com;
Investors: John Elicker, Investor Relations, +1-212-546-3775,
john.elicker@bms.com, or Suketu Desai, Investor Relations,
+1-609-252-5796, suketu.desai@bms.com, all for Bristol-Myers
Squibb Company
|
